The 5 Minute Urology Consult 3rd Ed.

TUNICA ALBUGINEA/PARATESTICULAR TUMORS AND CYSTS

John L. Phillips, MD, FACS

Vladimir A. Valera, MD, PhD

BASICS

DESCRIPTION

• Lesions can arise from the paratesticular regions of the scrotum and testes. These soft tissues include

– tunica albugenia, tunica vaginalis, spermatic cord structures and mullerian remnants (eg, appendix testis or appendix epididymis)

– Benign 70%

Lipomas (90% of adult PT tumors)

Adenomatoid tumors 30%

Tunica albugenia cysts

Leiomyomas

Cystadenomas

Adrenal rests

Cysts of the appendix testis

Hamartomas/pseudotumors (rare)

– Malignant 30%

Leiomyosarcoma

Rhabdomyosarcoma (RMS) 24–40%

Liposarcoma

Malignant mesothelioma (MM)

Desmoplastic round cell tumor (DRCT)

EPIDEMIOLOGY

Incidence

• Rare, true incidence unknown

• Europe: 5–7 cases per million

• Adenomatoid tumors typically seen in 4th decade

• Leiomyosarcoma and MM peak in 5th–7th decade

• RMS: Bimodal

– 2–6 yr & 15–19 yr

Most common tumor of lower GU tract in the 1st 2 yr

– 5–7 cases/10 million children

Prevalence

• Reported in 1 of 20–40 orchiectomy specimens

– China: 4.7% of pediatric scrotal tumors over 12 yr (1)

– High in SW Nigeria: 38.5% of adult orchiectomy specimens over 17 yr (2)

RISK FACTORS

• Cryptorchidism not a risk factor for PT tumors

• Asbestos exposure may be risk factor for MM

• Cystadenomas seen in Von Hippel–Lindau (VHL) disease are typically bilateral

• Parental cocaine or THC use seen in pediatric RMS

Genetics

• RMS, embryonal subtype, frequently has monosomy of chromosome 11.

– Alveolar subtypes express t(2;13)(q35;q14) or t(1;13)(p36;q14) and bodes poorly

• DRCT express t(11;22)(p13;p12) fusions of EWS and WT1.

PATHOPHYSIOLOGY

• Arise from epithelial, mesothelial, or mesenchymal tissues

– Epididymis

Adenomatoid tumor

Cystadenoma (1/3 occur in VHL)

– Spermatic cord

Sarcoma (arise from undifferentiated mesoderm)

Adrenal rest (found incidentally during hernia repair)

Lipoma/leiomyoma/liposarc, etc.

– Tunica vaginalis (TV)

MM

ASSOCIATED CONDITIONS

• Germline conditions

– Von Hippel–Lindau disease

Infertility low even in bilateral cases

– Li–Fraumeni syndrome confers predisposition

• Somatic (ie, acquired) conditions

– Ipsilateral hydrocele (eg, reactive)

– Ipsilateral hernia (ie, cause for exploration)

– Pulmonary mesothelioma (and asbestos exposure in MM of the TV)

– Scrotal trauma

– Epididymitis–orchitis

– Infertility (ie, cause for workup or exploration)

GENERAL PREVENTION

No known environmental or occupational risk

DIAGNOSIS

HISTORY

• Slowly growing inguinal or scrotal mass

• Often painless

• Found in workup for hernia

• Found in evaluation of scrotal trauma or inflammatory/infectious scrotal conditions

PHYSICAL EXAM

• Inguinal or scrotal mass

• Testis often discrete and normal

– Adenomatoid tumors may occur more inferiorly on the testis.

– Superior pole tumors may mimic a spermatocele (SC)

• Evaluate for hernia, hydrocele, SC, and varicocele

ALERT

Fixation to inguinal canal or testis suggests malignancy. Prepare for and rule out sarcoma.

• Fixation or involvement of testis and not the chord suggests primary testicular or MM

– Rule out germ cell tumor or MM

• Large size >5 cm suggests RMS

ALERT

• Transillumination does not rule out tumor

• Rule out secondary or, more rare, primary lymphoma.

DIAGNOSTIC TESTS & INTERPRETATION

Lab

• Rule out concurrent infection or inflammation

– Urinalysis

– Urine culture

• Rule out concurrent mycobacterial infection (can mimic tumor)

– PPD history

– Chest x-ray (rule out granulomas, tumor)

• Assess testicular germ cell tumor (GCT) markers

– AFP

– β-hCG

– LDH

– PLAP

Imaging

• Scrotal ultrasound critical in evaluation

– Differentiate testicular from PT process

3D or elastosonography not necessary if tumor distinctly separate from testis

– Solid masses require exploration

– Cystic structures such as tunica albuginea cyst may be monitored serially

• CT scan of the chest, abdomen, and pelvis required when malignancy suspected and to rule out metastasis in cases of known malignancy

Diagnostic Procedures/Surgery

• Fine needle aspiration may lead to false negatives or positives

• Solid lesions require inguinal approach

• Benign lesions

– Observation

– Testis-sparing surgery

• Malignant or suspicious lesions

– Radical orchiectomy, inguinal approach

High dissection to internal ring

Early vascular control

Resection of adherent structures

Skin

Fascia

Muscle

Pathologic Findings

• Benign lesions usually need low power H&E

– Adenomatoid tumor

Well circumscribed

May involve tunica albuginea

Benign appearing cords and cystic tubules lined by eosinophilic cells with small nuclei

– Papillary cystadenoma

Well circumscribed

Brown fronds within cystic space

May have clear cells that resemble renal cell carcinoma (commonly associated with VHL)

• Malignant lesions may need electron microscopy

– MM

Friable, multicystic within hydrocele

Epithelioid, papillary, tubulopapillar pattern

Fibrovascular core

– Rhabdomyosarcoma (RMS)

Embryonal in 90%

Alveolar

Mixed pleiomorphic

– Desmoplastic round cell tumor (DRCT)

Firm, white, often near epididymis

Small blue cells in nests and cords

Mitotically active

– Leiomyosarcoma

Intersecting bundles of smooth muscle cells

Atypical and mitotically active

– Liposarcoma

Large, atypical cells, large nuclei

Fibrous septae

Lipoblasts present

DIFFERENTIAL DIAGNOSIS

• Epididymal tumors (rare)

– Adenocarcinoma

– Cystadenoma

• Proliferative folliculitis

– Resemble nodular fasciitis

– Incidental at herniorrhaphy

• Hernia, direct or indirect

• Hydrocele

• Lymphadenopathy

• Metastatic tumor

• Squamous cell carcinoma (scrotal skin)

• Sperm granuloma, usually post-vasectomy

• Testis tumor

• Tunica albuginea cyst

• Vasitis nodosa

TREATMENT

GENERAL MEASURES

• Cystic PT structures are treated with observation or rarely conservative excision

• Solid masses usually require excision

– Benign: use testicle sparing surgery (TSS)

– Malignant

TNM staging

Local excision

Adjuvant chemotherapy for RMS

Adjuvant local radiation for other sarcomas

MEDICATION

First Line

• Malignant rhabsomyosarcoma (RMS)

– Vincristine

– Dactinomycin

– Cyclophosphamide

MESNA for bladder protection

Second Line

N/A

ADDITIONAL TREATMENT

Radiation Therapy

Reserved for local adjuvant or salvage control of malignant PT sarcomas

Additional Therapies

• Secondary resection

– Local recurrence of benign lesions

– Local recurrence of malignant lesions if localized, no evidence of metastatic disease, and radiotherapy not given

Complementary & Alternative Therapies

N/A

ONGOING CARE

PROGNOSIS

• Benign lesions

– Resection is usually curative

– Fertility can be maintained

• Malignant lesions

– RMS

Favorable prognosis in children

Stage I in 60–80%

Unfavorable prognosis in adults and children >10 yr

– DCRT unfavorable prognosis with nodal and pulmonary metastasis

– Mesothelioma. Aggressive; similar to peritoneal mesothelioma

– Lipo-/leiomyosarcoma

Excellent prognosis but may recur locally and require retreatment

Metastases exceedingly rare, reportable

COMPLICATIONS

• General as seen for inguinal surgery:

– Secondary hernia

– Infection

– Hematoma

– Pain

• Loss of testis after testicular sparing surgery (TSS) (rare)

• Infertility (eg, after excision of bilateral cystadenoma or epididymal masses in VHL)

FOLLOW-UP

Patient Monitoring

• Benign lesions

– Physical exam semiannual and self-exam yearly

• Malignant lesions

– Liposarcomas rarely metastasize but can recur locally

– RMS

Interdisciplinary oncologic team (3)

Serial imaging

40% metastasize to retroperitoneum

Role of RPLND in RMS controversial

Patient Resources

• National Cancer Institute

– Childhood Rhabdomyosarcoma Treatment

www.cancer.gov/cancertopics/pdq/treatment/childrhabdomyosarcoma/patient

• Testicular Self-Exam

www.nlm.nih.gov/medlineplus/ency/article/003909.htm

• Liddy Schriver Sarcoma Initiative

sarcomahelp.org (Accessed August 22, 2014)

REFERENCES

1. Park SB, Lee WC, Kim JK, et al. Imaging features of benign solid testicular and paratesticular lesions. Eur Radiol. 2011;21:2226–2234.

2. Salako AA, Onakpoya UU, Osasan SA, et al. Testicular and para-testicular tumors in south western Nigeria. Afr Health Sci. 2010;10:14–17.

3. Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg. 2001;10:146–152.

ADDITIONAL READING

Vagnoni V, Brunocilla E, Schiavina R, et al. Inguinal canal tumors of adulthood. Anticancer Res. 2013;33(6):2361–2368.

See Also (Topic, Algorithm, Media)

• Epididymis, Mass (Epididymal Tumor and Cysts)

• Paratesticular Tumors

• Rhabdomyosarcoma, Pediatric (Sarcoma Botryoides)

• Scrotum and Testicle, Mass

• Spermatic Cord Mass and Tumors

• Spermatocele

CODES

ICD9

• 214.8 Lipoma of other specified sites

• 239.5 Neoplasm of unspecified nature of other genitourinary organs

• 608.89 Other specified disorders of male genital organs

ICD10

• D49.5 Neoplasm of unspecified behavior of other genitourinary organs

• N44.1 Cyst of tunica albuginea testis

• N50.8 Other specified disorders of male genital organs

CLINICAL/SURGICAL PEARLS

• Most common adult benign paratesticular tumor: Lipoma.

• Most common adult malignant paratesticular tumor: Liposarcoma.

• Most common pediatric PT tumor is malignant RMS (rhabdomyosarcoma).

• Cure rate of RMS with multimodality therapy: 90%.



If you find an error or have any questions, please email us at admin@doctorlib.org. Thank you!